These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28854074)

  • 1. Implementation of a New Clinic-Based, Pharmacist-Managed PCSK9 Inhibitor Consultation Service.
    Atanda A; Shapiro NL; Stubbings J; Groo V
    J Manag Care Spec Pharm; 2017 Sep; 23(9):918-925. PubMed ID: 28854074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advancing Patient Care Through Specialty Pharmacy Services in an Academic Health System.
    Bagwell A; Kelley T; Carver A; Lee JB; Newman B
    J Manag Care Spec Pharm; 2017 Aug; 23(8):815-820. PubMed ID: 28737983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacist-managed virtual consult service for patients with rheumatologic conditions requiring specialty or infused medications.
    Sasnovskaya V; Kumor LM; Stubbings J; Chevalier A
    Am J Health Syst Pharm; 2022 Jan; 79(1):e41-e49. PubMed ID: 34170283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates.
    Reynolds VW; Chinn ME; Jolly JA; Kelley TN; Peter ME; Choi L; Nwosu S; Leon BC; Zuckerman AD
    J Clin Lipidol; 2019; 13(2):254-264. PubMed ID: 30745204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal follow-up schedule for patients taking PCSK9 monoclonal antibodies in a health system: Analysis of specialty pharmacy clinical interventions.
    Avlasevich V; Pilat S; Reindel K; Manou K; Trawinski A; Rightmier E
    Am J Health Syst Pharm; 2024 Jun; 81(13):e358-e364. PubMed ID: 38347759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of an integrated pharmacist collaborative care model in specialty disease state clinics.
    Stroedecke N; Lee J; Stutsky M; Boothe K; Tong K; Luon S; Sawant V; Renauer M
    Am J Health Syst Pharm; 2022 Nov; 79(22):2047-2052. PubMed ID: 35913890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of an integrated ambulatory care pharmacist collaborative care workflow model in specialty clinics in a large academic health system.
    Lee J; Tong K; Stroedecke N; Monestime S; Eom E; Stutsky M; Boothe K; Luon S; Sawant V; Renauer M
    Am J Health Syst Pharm; 2023 Jun; 80(13):842-851. PubMed ID: 37144568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System.
    An J; Niu F; Zheng C; Rashid N; Mendes RA; Dills D; Vo L; Singh P; Bruno A; Lang DT; Le PT; Jazdzewski KP; Aranda G
    J Manag Care Spec Pharm; 2017 Jun; 23(6):700-712. PubMed ID: 28530526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacist-administered long-acting injectable PCSK9 service: A solution to improve patient access and adherence.
    Dixon DL; Saseen JJ
    J Am Pharm Assoc (2003); 2021; 61(3):e83-e85. PubMed ID: 33384242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacist-managed multistep order transmittal for electronic specialty prescriptions reduces represcribing burden in ambulatory clinics: A retrospective cohort pilot study.
    Nguyen SH; Grindeland CJ; Leedahl DD
    J Manag Care Spec Pharm; 2022 Jul; 28(7):778-785. PubMed ID: 35737857
    [No Abstract]   [Full Text] [Related]  

  • 11. Improvement in safety monitoring of biologic response modifiers after the implementation of clinical care guidelines by a specialty.
    Hanson RL; Gannon MJ; Khamo N; Sodhi M; Orr AM; Stubbings J
    J Manag Care Pharm; 2013; 19(1):49-67. PubMed ID: 23383700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacist implementation of a transitions of care electronic referral process to provide hand-off between inpatient and outpatient settings.
    Martirosov AL; Seitllari K; Kaurala S; MacDonald N
    J Am Pharm Assoc (2003); 2020; 60(1):112-116.e1. PubMed ID: 31690512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of embedding a pharmacist in a dermatology clinic on outcomes in a specialty pharmacy.
    Penick T; Hawkins T; O'Reilly E; Maniyar H; Maier C; McPheeters C
    J Am Pharm Assoc (2003); 2023; 63(2):661-666. PubMed ID: 36464555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Clinical Pharmacy Interventions to Reduce Outpatient Use of High-Risk Medications in the Elderly.
    Weddle SC; Rowe AS; Jeter JW; Renwick RC; Chamberlin SM; Franks AS
    J Manag Care Spec Pharm; 2017 May; 23(5):520-524. PubMed ID: 28448781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Droxidopa management by an integrated health-system specialty pharmacy team.
    Livezey SN; Shah NB; DeClercq J; Keefe J; Choi L; Shibao C; Zuckerman AD
    J Am Pharm Assoc (2003); 2022; 62(6):1904-1911. PubMed ID: 35787811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a Pharmacist-Driven Monitoring Program and Electronic Health Record on Bleeding Log Completeness and Documentation.
    Shay B; Kennerly-Shah J; Neidecker M; Beatty S; Witkoff L; Brown N; Kraut E
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1034-1039. PubMed ID: 30247104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Michigan Pharmacists Transforming Care and Quality: Developing a Statewide Collaborative of Physician Organizations and Pharmacists to Improve Quality of Care and Reduce Costs.
    Choe HM; Lin AT; Kobernik K; Cohen M; Wesolowicz L; Qureshi N; Leyden T; Share DA; Darland R; Spahlinger DA
    J Manag Care Spec Pharm; 2018 Apr; 24(4):373-378. PubMed ID: 29578853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Evaluation of the Effect of Pharmacist-Led Comprehensive Chemotherapy Consultation Services on Outpatient Appointment Adherence.
    Sebring EJ; Rudisill MA; Bates JS; Auten JJ; Urick BY; Clark SM
    J Manag Care Spec Pharm; 2020 Jun; 26(6):723-727. PubMed ID: 32463774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system.
    Ji C; Bai J; Zhou J; Zou Y; Yu M
    Br J Clin Pharmacol; 2022 Dec; 88(12):5317-5325. PubMed ID: 35818959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.